ArticleRMD open2026
Mortality incidence in spondyloarthritis: real-world evidence using the TriNetX Global Collaborative Network.
Article in RMD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess all-cause mortality in patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA), and to examine the influence of sex, comorbidities and biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in a large, multinational, real-world cohort.
methodsThis retrospective cohort study used the TriNetX Global Collaborative Network, comprising anonymised electronic health records from over 150 million individuals across >100 healthcare organisations worldwide. Adults with ≥2 diagnoses of ankylosing spondylitis or arthropathic psoriasis between 2010 and 2020 were included. Propensity score matching accounted for demographics and comorbidities. Kaplan-Meier survival analysis and Cox proportional hazards models were used to estimate HRs for all-cause mortality, comparing axSpA and PsA cohorts with each other and with matched general population controls.
resultsWe identified 32 368 patients with axSpA, 52 402 patients with PsA and 9 742 949 controls. Compared with the general population, mortality risk was significantly higher in axSpA (HR 1.71, 95% CI 1.61 to 1.81) and PsA (HR 1.26, 95% CI 1.20 to 1.32). Mortality was 42% greater in axSpA than PsA (HR 1.42, 95% CI 1.34 to 1.51). Male sex was associated with increased mortality (axSpA HR 1.65; PsA HR 1.26). Treatment with b/tsDMARDs, particularly tumour necrosis factor (TNF) inhibitors, reduced mortality by 47% in axSpA and 38% in PsA compared with untreated patients.
conclusionAll-cause mortality remains elevated in axSpA and PsA, particularly in axSpA. Male sex predicts poorer survival, whereas TNF inhibitor therapy is associated with improved outcomes. Early, targeted management may help reduce mortality in spondyloarthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.